Project Grant R01HL180797
Award Date 9/1/26
Completion Date 5/31/31
Dollars Obligated $778K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
La Jolla, CA 92093, USA
Similar Awards
- The National Heart, Lung, and Blood Institute awarded the University of California, Los Angeles $783,885 for Project Grant R01HL181589 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research on the role of NTRK2 isoforms in alveolar injury and repair related to bronchopulmonary dysplasia (BPD), a chronic lung disease affecting approximately 10,000 premature infants annually in the United States. The research employs multiomic profiling...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $744,157 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to elucidate the molecular mechanisms of lung cell fate determination in the conducting airways and alveolar epithelium. The research investigates how SOX9+ progenitors produce SOX2+ cells to form conducting airways and generate AT1/2 cells to form alveoli, with emphasis on Hippo signaling and...
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $766,557 for a Project Grant (R01HL188011) on August 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into bronchiolization—the takeover of alveoli by airway cell types—a hallmark of interstitial lung diseases including idiopathic pulmonary fibrosis. The project uses CRISPR/Cas9 genome editing to generate mouse models carrying patient mutations in...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $731,287 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate airway epithelial cell reprogramming mechanisms in chronic lung allograft dysfunction. The research will test whether mTOR signaling drives chronic lung allograft dysfunction through airway epithelial cell reprogramming and examine mTOR as a predictive biomarker of allograft...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $778,504 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate molecular mechanisms controlling lung capillary speciation, plasticity, and function during early postnatal development. The research examines how distinct subtypes of lung capillary endothelial cells—CAP1 and CAP2—contribute to alveolar formation and repair after injury during...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $516,181 on September 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to conduct a prospective observational ancillary study nested within the MIDAS (Milrinone for Prevention of Post-Ligation Cardiac Syndrome) clinical trial. The study uses non-invasive bedside monitoring techniques—near-infrared spectroscopy (NIRS), lung ultrasound (LUS), and targeted neonatal echocardiography...
- The National Heart, Lung, and Blood Institute awarded The Regents of the University of California, San Francisco $1,097,760 on February 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund a Project Grant (R35HL183538) investigating mechanisms of age-related pulmonary fibrosis and lung regeneration. The research program addresses idiopathic pulmonary fibrosis (IPF), a progressive disease affecting approximately 200,000 patients annually in the United States with...
- The National Heart, Lung, and Blood Institute awarded $448,250 to The Research Foundation For The State University Of New York on May 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop and evaluate a lung-targeted immunomodulatory messenger RNA therapy for acute respiratory distress syndrome. The award funds development of an IL-10 mRNA therapeutic delivered via sulfonium lipid nanoparticles, a novel lung-targeting technology designed to suppress...
- The National Heart, Lung, and Blood Institute, part of the Department of Health and Human Services, awarded $795,464 to The Regents of the University of California, San Francisco on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds research into adaptive-like natural killer cells in pulmonary cytomegalovirus reactivation. The project investigates whether local cytomegalovirus-specific natural killer cell immune responses in the lungs potentiate...
- The National Heart, Lung, and Blood Institute (NHLBI) of the Department of Health and Human Services awarded $1,545,864 to the University of Pittsburgh on August 7, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to fund Project Grant R01HL187347, an investigation into immune-mediated lung repair following early life respiratory viral infection. The research defines mechanisms of viral lower respiratory tract infection (LRTI)–driven lung damage and repair in neonates, with...